IN8bio (INAB) Expected to Announce Quarterly Earnings on Wednesday

IN8bio (NASDAQ:INAB) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect IN8bio to post earnings of ($0.59) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). On average, analysts expect IN8bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IN8bio Price Performance

Shares of IN8bio stock opened at $1.50 on Monday. The business has a fifty day simple moving average of $1.59 and a 200-day simple moving average of $1.83. IN8bio has a fifty-two week low of $1.17 and a fifty-two week high of $5.61. The firm has a market cap of $14.77 million, a price-to-earnings ratio of -0.34 and a beta of 0.08.

Wall Street Analyst Weigh In

Several equities research analysts have commented on INAB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of IN8bio in a research note on Friday, March 13th. Finally, Zacks Research upgraded shares of IN8bio to a “hold” rating in a report on Thursday, January 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On IN8bio

A number of institutional investors and hedge funds have recently modified their holdings of INAB. Two Sigma Investments LP purchased a new stake in shares of IN8bio during the third quarter valued at $107,000. Citadel Advisors LLC acquired a new stake in IN8bio during the 3rd quarter worth about $54,000. Franklin Resources Inc. raised its holdings in IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after buying an additional 724,637 shares during the period. HRT Financial LP purchased a new stake in IN8bio during the fourth quarter valued at about $34,000. Finally, Alyeska Investment Group L.P. lifted its stake in IN8bio by 1,060.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after buying an additional 875,000 shares in the last quarter. 92.05% of the stock is owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.